TNFα inhibitor biosimilars associated with alopecia areata. Case-based review

Alopecia areata (AA) is a common non-scaring hair loss associated with many inflammatory and autoimmune disorders. Anti-tumor necrosis factor alpha (TNF alpha) therapy is used to treat many chronic inflammatory disorders and has been proven to be effective and relatively safe. However, several immune-mediated skin reactions have been described with the use of TNF alpha inhibitors, among them AA. In this report, we describe two patients, a 32-year-old woman with ankylosing spondylitis and a 48-year-old man with rheumatoid arthritis who were both treated with SB4 (Benepali (R)), an etanercept biosimilar, and developed AA, 6 and 12 months respectively after the initiation of TNF alpha blocker biosimilar. These, are the first two cases of AA development during TNF alpha inhibitors biosimilar. Thus, physicians when dealing with patients treated with these agents, should be aware of possible immune skin reactions, among them AA. To this end, a close follow-up and monitoring is mandatory.

Automated summary

This report describes two cases of AA development associated with TNFα inhibitor biosimilar therapy, highlighting the need for physicians to be aware of potential immune skin reactions in patients receiving these medications.